NCT02121041

Brief Summary

The purpose of this study is to compare the effectiveness of ambulatory blood pressure monitoring to usual care (blood pressure measurement in the office) in diagnosing and managing hypertension.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started May 2014

Typical duration for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 16, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 23, 2014

Completed
8 days until next milestone

Study Start

First participant enrolled

May 1, 2014

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
6 months until next milestone

Results Posted

Study results publicly available

December 19, 2016

Completed
Last Updated

February 10, 2017

Status Verified

December 1, 2016

Enrollment Period

1.3 years

First QC Date

April 16, 2014

Results QC Date

October 25, 2016

Last Update Submit

December 19, 2016

Conditions

Keywords

HypertensionBlood PressureAmbulatory Blood Pressure Monitoring

Outcome Measures

Primary Outcomes (1)

  • 24 Hour Blood Pressure Average at the End of 4 Month Participation.

    Participants will be on study average of 4 months.

Study Arms (2)

Usual Care

NO INTERVENTION

Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.

ABPM Guided

ACTIVE COMPARATOR

Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.

Drug: AmlodipineDrug: ChlorthalidoneDrug: Losartan

Interventions

Amlodipine 5 mg or 10 mg

Also known as: Norvasc
ABPM Guided

Chlorthalidone 12.5 mg or 25 mg

Also known as: Thalitone
ABPM Guided

Losartan 50 mg or 100 mg

Also known as: Cozaar
ABPM Guided

Eligibility Criteria

Age30 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 30 years and ≤ 65 years
  • Most recent (within 14 days) clinic systolic BP 126-150 mm Hg
  • Able/willing to wear a BP monitor for 24 hours on multiple occasions
  • Able/willing to take daily anti-hypertensive medication if indicated
  • Able to read and speak English

You may not qualify if:

  • Pregnant or trying to become pregnant
  • Known heart disease
  • History of persistent atrial fibrillation
  • Currently taking antihypertensive medication
  • Currently taking Simvastatin \> 20mg daily
  • Clinician recommends against participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of North Carolina

Chapel Hill, North Carolina, 27599, United States

Location

MeSH Terms

Conditions

Hypertension

Interventions

AmlodipineChlorthalidoneLosartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

DihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsBenzophenonesPhthalimidesImidesKetonesSulfonesSulfur CompoundsIsoindolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingBiphenyl CompoundsImidazolesAzolesTetrazoles

Results Point of Contact

Title
Dr. Anthony Viera
Organization
UNC Chapel Hill

Study Officials

  • Anthony J Viera, MD, MPH

    University of North Carolina

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Distinguished Associate Professor, Family Medicine

Study Record Dates

First Submitted

April 16, 2014

First Posted

April 23, 2014

Study Start

May 1, 2014

Primary Completion

September 1, 2015

Study Completion

July 1, 2016

Last Updated

February 10, 2017

Results First Posted

December 19, 2016

Record last verified: 2016-12

Data Sharing

IPD Sharing
Will not share

Locations